Evidence map›Paper›PMID 32443602›Full record

ReviewNanomaterials (Basel, Switzerland)2020

The Impact of Engineered Silver Nanomaterials on the Immune System.

Neethu Ninan, Nirmal Goswami, Krasimir Vasilev

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Review
  2. Article
  3. Metallic nanomedicine in cancer immunotherapy.Acta pharmaceutica Sinica. B · 2025
    Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Biomaterials for Drug Delivery and Human Applications.Materials (Basel, Switzerland) · 2024
    Review
  12. Cu-doped TiOJournal of nanobiotechnology · 2023
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Neethu NinanUnit of Science, Technology, Engineering and Mathematics (STEM), The University of South Australia, Mawson Lakes, SA 5095, Australia.
Nirmal GoswamiUnit of Science, Technology, Engineering and Mathematics (STEM), The University of South Australia, Mawson Lakes, SA 5095, Australia.
Krasimir VasilevUnit of Science, Technology, Engineering and Mathematics (STEM), The University of South Australia, Mawson Lakes, SA 5095, Australia.

Funding

Australian Research Council DP15104212National Health and Medical Research Council APP1032738National Health and Medical Research Council APP1122825
6 · The paper itself

Abstract

Over the last decades there has been a tremendous volume of research efforts focused on engineering silver-based (nano)materials. The interest in silver has been mostly driven by the element capacity to kill pathogenic bacteria. In this context, the main area of application has been medical devices that are at significant risk of becoming colonized by bacteria and subsequently infected. However, silver nanomaterials have been incorporated in a number of other commercial products which may or may not benefit from antibacterial protection. The rapid expansion of such products raises important questions about a possible adverse influence on human health. This review focuses on examining currently available literature and summarizing the current state of knowledge of the impact of silver (nano)materials on the immune system. The review also looks at various surface modification strategies used to generate silver-based nanomaterials and the immunomodulatory potential of these materials. It also highlights the immune response triggered by various silver-coated implantable devices and provides guidance and perspective towards engineering silver nanomaterials for modulating immunological consequences.

Indexed as

anti-inflammatoryimmune cellsimplantspro-inflammatorysilver nanomaterials

Identifiers

PMID32443602
PMCPMC7712063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.